2TK Stock Chart & Stats
€2.88
€0.04(1.27%)
At close: 4:00 PM EDT
€2.88
€0.04(1.27%)
Day’s Range― - ―
52-Week Range€1.17 - €3.70
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
€224.44M
Enterprise Value€398.44
Total Cash (Recent Filing)€88.76M
Total Debt (Recent Filing)€467.00K
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Nov 18, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding81,261,154
10 Day Avg. Volume15
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.20Price Target Upside184.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal debt reduces solvency and interest-burden risk while the company funds clinical development. This provides greater financial flexibility than a highly leveraged biotech, although equity funding remains necessary.
Targeted Clinical DevelopmentA focused mechanism addressing graft rejection and broad immunosuppression could support differentiated clinical positioning if efficacy and safety are demonstrated. The platform also offers potential across transplantation and autoimmune indications.
Capital-Raising FlexibilityThe larger authorized-share pool gives Eledon additional flexibility to fund trials, pursue transactions, or support corporate initiatives. This can reduce execution constraints as development programs advance, though issuance may dilute holders.
Bears Say
No Commercial RevenueEledon has no recurring product sales to help fund operations, leaving the company dependent on external capital while its lead candidate remains in development. This increases execution risk and makes future funding conditions strategically important.
Accelerating LossesDeepening losses show that Eledon remains far from breakeven and that operating expenses are not yet supported by commercial revenue. Sustained losses could require repeated financing and limit the company’s strategic flexibility.
Persistent Cash Burn And Dilution RiskLarge ongoing cash consumption and a shrinking equity base indicate a tightening funding runway. With no operating cash generation, additional equity issuance may become necessary, creating continuing dilution risk for shareholders.
Eledon Pharmaceuticals News
2TK FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was €1.17 and its highest was €3.70 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Eledon Pharmaceuticals’s market cap is €224.44M.
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is Nov 18, 2026 which is in 80 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on Aug 13, 2026. The company reported -€0.233 earnings per share for the quarter, missing the consensus estimate of -€0.136 by -€0.097.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -0.16.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 81,261,154 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -€0.233 in its last earnings report, missing expectations of -€0.136. Following the earnings report the stock price went down -1.887%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:2TK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.20 (184.70% Upside)
€8.20 (184.70% Upside)
Blogger Sentiment
Bullish
DE:2TK Sentiment 100%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
2TK Stock 12 Month Forecast
Average Price Target
€8.20
▲(184.70% Upside)
Technical Analysis
MacroGenics
―
Fate Therapeutics
―
ProQR
―
Bicycle Therapeutics
―
SAB Biotherapeutics
―